We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PARR:NYSEPar Pacific Holdings, Inc. Common Stock Analysis

Data as of 2026-06-18 - not real-time

$49.61

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Par Pacific trades well below its industry peers on a price‑to‑earnings basis, suggesting a compelling value angle, yet a discounted cash‑flow model places the fair value far beneath the current market price, flagging potential overvaluation. The stock exhibits a bearish MACD divergence and a negative beta, indicating limited upside momentum and an inverse relationship to broader market moves. Volatility is elevated, with a 30‑day swing exceeding forty percent, underscoring heightened price swings. Recent analyst sentiment turned more optimistic, with Mizuho upgrading its outlook and price targets implying a sizable upside despite the technical weakness. Strong operating cash flow and a respectable return on equity highlight solid underlying profitability. However, the company carries a high debt‑to‑equity ratio and modest cash balances, which could constrain flexibility in a tightening credit environment. The support level aligns closely with today’s price, offering limited downside cushion, while resistance sits well above current levels. Crack spread dynamics have driven a remarkable year‑to‑date rally, but the sustainability of this spread premium remains uncertain. The energy sector faces regulatory headwinds related to emissions and renewable transition, adding a layer of sector‑specific risk. Liquidity indicators show a decreasing volume trend, suggesting that large trades could impact price more than usual. Overall, the stock sits at a crossroads between strong fundamentals and technical softness, with market sentiment tilting toward optimism despite valuation concerns.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD and proximity to support
  • Elevated volatility and decreasing volume
  • Recent analyst upgrade adds upside but not enough to offset technical weakness

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Low P/E relative to industry and strong cash flow generation
  • Potential for crack spread normalization to sustain earnings
  • Analyst price targets indicate significant upside potential

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Overvalued DCF fair value versus market price
  • Regulatory and sector transition risks
  • Solid return on equity but high leverage may limit long‑term flexibility

Key Metrics & Analysis

Financial Health

Revenue Growth4.50%
Profit Margin6.02%
P/E Ratio5.6
ROE33.32%
ROA9.42%
Debt/Equity87.47
P/B Ratio1.6
Op. Cash Flow$406.0M
Free Cash Flow$118.5M
Industry P/E20.0

Technical Analysis

TrendNeutral
RSI32.0
Support$49.60
Resistance$62.23
MA 20$55.59
MA 50$59.96
MA 200$46.46
MACDBearish
VolumeDecreasing
Fear & Greed Index91.11

Valuation

Fair Value$14.44
Target Price$75.00
Upside/Downside51.18%
GradeOvervalued
TypeBlend

Risk Assessment

Beta-0.41
Volatility43.64%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.